A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback